Biofrontera AG has released its financial outlook following the reorganization of its collaboration with Biofrontera Inc. For the fiscal year 2025, the company anticipates revenues ranging between 17 to 20 million euros. Additionally, Biofrontera AG projects an EBITDA of 1.5 to 3.5 million euros for the same period. The company is based in Leverkusen, Germany, and is publicly traded with its stock listed on various German stock exchanges including those in Düsseldorf, Frankfurt, and others.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.